FOLH1 and prostate carcinoma: This manual has been created for a clinical trial of an astatine-labeled prostate-specific membrane antigen (PSMA) ligand ([211At]PSMA-5) as a treatment for prostate cancer to ensure the safe handling of the drug in compliance with the principles of safety guidelines stipulated by the relevant laws and regulations.